Table 5.
Population estimates of structural and derived pharmacokinetic parameters for piperaquine in 85 patients with uncomplicated falciparum and vivax malaria, grouped according to age1
| Adults | Children | |
|---|---|---|
| Vc/F (l kg–1) | 14.5 (46%) | 19.7 (51%) |
| ka (h–1) | 0.083 (108%) | 0.075 (44%)2 |
| lag (h) | 0.49 (179%) | – |
| kel (h–1) | 0.058 (78%) | 0.090 (52%) |
| k12 (h–1) | 0.19 (57%) | 0.33 (75%) |
| k21 (h–1) | 0.0056 (131%) | 0.0099 (85%) |
| t1/2,λ1 (h) | 2.6 (2.4–3.0) | 1.7 (1.3–1.9) |
| t1/2,z (h) | 543 (457–663) | 324 (245–438) |
| t1/2,abs (h) | 9.09 (7.67–15.4) | 9.26 (9.25–9.27) |
| CL/F (l h–1 kg–1) | 0.90 (0.79–1.02) | 1.85 (1.29–2.30) |
| Vdss/F (l kg–1) | 574 (371–711) | 614 (332–1205) |
1
Results as population mean and coefficient of variation (CV%) or, because of the presence of outlying values, median and (interquartile range)
2
Parameter estimated with a log normal distribution.